The Journal Record

NORMAN – Ekips Technologies has received a U.S. patent for a method for determining concentrations of biomarkers in exhaled breath.

The patent issued by the United State Patent and Trademark office is for a method for obtaining reliable concentrations of specific trace gases. The patented method, currently employed in Ekips’ Breathmeter product, eliminates the need for routine instrument calibration.

Ekips is also investigating the use of the Breathmeter instrument for detection of exhaled biomarkers related to cancer and infectious disease.

“Breath analysis has the potential to become a routine, non-invasive indicator of human health," said Chad Roller, vice president of research for Norman-based Ekips. "The issuance of this patent puts Ekips in a key position to bring user friendly breath analysis products to market.”